Nath Bio-Genes (India) Ltd. AI Stock Analysis
Want to see IN:NATHBIOGEN full AI Analyst Report?
Nath Bio-Genes (India) Ltd. (NATHBIOGEN) AI Stock Analysis
Nath Bio-Genes (India) Ltd.
(NSE:NATHBIOGEN)
The score is supported by strong balance-sheet quality, low leverage, revenue growth, and attractive valuation. These strengths are materially offset by negative cash flow and mixed-to-weak technical trends, resulting in a moderately positive overall assessment.
Nath Bio-Genes (India) Ltd. (NATHBIOGEN) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 2.69B
- Dividend Yield
- 1.40%
- Average Volume (3M)
- 1,005
- Price to Earnings (P/E)
- 7.7
- Beta (1Y)
- 1.02
- Revenue Growth
- 21.02%
- EPS Growth
- -3.13%
- Country
- India
- Employees
- 452
- Sector
- General
- Sector Strength
- 55
- Industry
- Agricultural Inputs
Nath Bio-Genes (India) Ltd. Business Overview & Revenue Model
Company Description
Nath Bio-Genes (India) Limited is dedicated to the development, preparation, and worldwide distribution of both hybrid and genetically modified (GM) seeds, catering to demand within India and internationally. Its business operations are organized int...
How the Company Makes Money
Nath Bio-Genes primarily makes money by selling seeds to the domestic agricultural market through its marketing and distribution network. Its main revenue stream is the sale of proprietary and third-party seeds (typically including hybrid seeds, wher...
Nath Bio-Genes (India) Ltd. Financial Statement Overview
Summary
Revenue growth, recovering profitability, strong equity, and low leverage support the score. However, sharply negative operating and free cash flow indicate significant working-capital strain.
Income Statement
72PositiveBalance Sheet
85Very PositiveCash Flow
45Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.90B | 4.45B | 3.65B | 2.48B | 3.01B | 2.78B |
| Gross Profit | 2.12B | 2.04B | 2.29B | 1.03B | 1.67B | 1.54B |
| EBITDA | 613.59M | 662.56M | 497.98M | 536.39M | 488.91M | -497.06M |
| Net Income | 386.75M | 416.30M | 386.00M | 396.19M | 350.11M | -673.38M |
Balance Sheet | ||||||
| Total Assets | 0 | 10.97B | 10.26B | 8.80B | 7.93B | 7.42B |
| Cash, Cash Equivalents and Short-Term Investments | 759.95M | 759.95M | 888.99M | 774.10M | 379.90M | 41.68M |
| Total Debt | 0 | 1.39B | 1.23B | 1.10B | 1.05B | 929.59M |
| Total Liabilities | -6.80B | 4.17B | 3.82B | 2.70B | 2.20B | 2.00B |
| Stockholders Equity | 6.80B | 6.80B | 6.44B | 6.10B | 5.73B | 5.42B |
Cash Flow | ||||||
| Free Cash Flow | -1.10B | -250.40M | 96.61M | 478.18M | 358.18M | -39.70M |
| Operating Cash Flow | -1.09B | -220.35M | 175.81M | 745.94M | 383.67M | 170.46M |
| Investing Cash Flow | -11.48M | -30.69M | -39.62M | -274.01M | -28.84M | -198.66M |
| Financing Cash Flow | 216.74M | 122.00M | -21.30M | -77.78M | -16.68M | -222.27M |
Nath Bio-Genes (India) Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NATHBIOGEN, the sentiment is Positive. The current price of 142.45 is above the 20-day moving average (MA) of 134.84, above the 50-day MA of 140.87, and below the 200-day MA of 152.30, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 60.18 is Neutral, neither overbought nor oversold. The STOCH value of 69.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NATHBIOGEN.
Nath Bio-Genes (India) Ltd. Peers Comparison
Overall Rating
IN:DHANUKA73Outperform
IN:SHARDACROP71Outperform
IN:INSECTICID66Neutral
IN:NATHBIOGEN66Neutral
IN:RALLIS63Neutral
IN:IPL55Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | INR 40.27B | 14.56 | ― | 0.22% | -0.06% | 0.75% | |
| 71Outperform | INR 65.69B | 10.22 | ― | 2.06% | 17.28% | 42.45% | |
| 66Neutral | INR 15.74B | 12.58 | ― | 0.92% | 1.26% | -16.43% | |
| 66Neutral | INR 2.71B | 7.70 | ― | 1.40% | 21.02% | -3.13% | |
| 63Neutral | INR 36.79B | 18.71 | ― | 1.59% | 6.82% | 11.93% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 55Neutral | INR 13.73B | 14.38 | ― | 0.63% | 2.89% | -9.47% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:NATHBIOGEN | Nath Bio-Genes (India) Ltd. | 142.45 | -21.33 | -13.02% | |
| IN:DHANUKA | Dhanuka Agritech Limited | 903.45 | -365.10 | -28.78% | |
| IN:INSECTICID | Insecticides (India) Limited | 541.00 | -128.01 | -19.13% | |
| IN:IPL | India Pesticides Ltd. | 119.20 | -59.68 | -33.37% | |
| IN:RALLIS | Rallis India Limited | 189.20 | -57.98 | -23.46% | |
| IN:SHARDACROP | Sharda Cropchem Ltd. | 728.15 | -53.22 | -6.81% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 12, 2026
